Alembic Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alembic Pharmaceuticals reported standalone revenue of Rs 6,651 crore for FY2026, up ~10% from Rs 6,033 crore in the prior year. Standalone PAT grew 27% to Rs 640 crore, aided by a one-time deferred tax credit of Rs 100.27 crore from a Finance Act amendment. Operating margin expanded to 16.82% from 15.74% on the standalone basis. Exceptional items included Rs 48.64 crore for new Labour Code provisions (gratuity/compensated absences impact) and an Rs 18.35 crore write-down for the Sikkim manufacturing facility classified as held for sale. The Board recommended dividend of Rs 12 per share (600%), up from Rs 11 per share. Auditors KKC & Associates issued an unmodified opinion on both standalone and consolidated results. Consolidated revenue stood at Rs 7,345 crore with PAT of Rs 675 crore.
The 27% PAT growth and margin expansion are positive, though FY2026 PAT was significantly boosted by the Rs 100 crore deferred tax credit. Excluding this one-time benefit, underlying earnings growth is more modest. The Sikkim facility write-down and Labour Code charge are non-recurring but signal ongoing restructuring in manufacturing footprint.